Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for emergence delirium in children
NCT05813106Phase 4Unknown
- Sponsor
- Security Forces Hospital
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in emergence delirium (ED) (2 arms), sponsored by Security Forces Hospital. Primary endpoint: Emergence delirium at 120 minutes. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
emergence delirium (ED)
Beyond the preview
Go deeper on NCT05813106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813106.